Recent Finacing
Recent Raise
Amytrx develops AMTX-100, a cell‑penetrating peptide targeting importins and inflammatory transcription factors; lead topical cream is in Phase 1/2b for atopic dermatitis, with other formulations preclinical.
Focus Areas
Total Raised
Funding round
See the team members at Amytrx Therapeutics.
